<DOC>
	<DOCNO>NCT00427570</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , vincristine , fluorouracil , semustine , work different way stop growth tumor cell , either kill cell stop dividing . Biological therapy , BCG , may stimulate immune system different way stop tumor cell grow . It yet know whether combination chemotherapy effective BCG treat colon cancer remove surgery . PURPOSE : This randomized phase III clinical trial study give fluorouracil together semustine vincristine see well work compare give BCG treat patient Dukes ' B Dukes ' C colon cancer remove surgery .</brief_summary>
	<brief_title>Fluorouracil , Semustine , Vincristine Compared With BCG Treating Patients With Dukes ' B Dukes ' C Colon Cancer That Has Been Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : I . Obtain information define subset colon cancer patient high risk recurrence . II . Correlate pathologic biologic parameter disease-free interval survival . III . Determine value surgical ancillary technique management colon cancer . IV . Compare disease-free interval survival curative resection vs. chemotherapy 5-fluorouracil/methyl-CCNU/vincristine vs. BCG immunotherapy . V. Relate total lymphocyte count course disease . VI . Determine feasibility conduct trial employ immunotherapy surgical adjuvant setting . VII . Identify appropriate future protocol base data generate study . OUTLINE : Randomized study patient Dukes Stage B C disease . All patient Dukes A D lesion enter Arm I . Arm I : No therapy follow surgery . Arm II : 3-Drug Combination Chemotherapy . 5-Fluorouracil , 5-FU , NSC-19893 ; Methyl-CCNU , MeCCNU , NSC-95441 ; Vincristine , VCR , NSC-67574 . Arm III : Immunotherapy . BCG-Pasteur , BCG , NSC-B116328 . PROJECTED ACCRUAL : Protocol close February 1984 .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Semustine</mesh_term>
	<mesh_term>BCG Vaccine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : See General Eligibility Criteria PATIENT CHARACTERISTICS : See General Eligibility Criteria</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>stage II colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
</DOC>